Fibronectin (Fn1) has been particularly linked to the accumulation of ECM proteins, and treatment with the SGLT2 inhibitor canagliflozin in individuals with type 2 diabetes and elevated urine ACR has been shown to downregulate plasma levels of fibronectin, thereby reducing the fibrosis biomarker (Heerspink et al., 2019). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.